Results from an updated analysis of the pivotal phase III NATALEE trial of Ribociclib ( Kisqali ) that underscore the ...

The first interim results of VARGADO, an ongoing non-interventional study in routine clinical practice in Germany evaluating the efficacy and ...

COSMIC-HF ( Chronic Oral Study of Myosin Activation to Increase Contractility in Heart Failure ) is a double-blind, randomized, placebo-controlled, ...

Data from a new analysis demonstrating that fewer heart failure patients with reduced ejection fraction ( HFrEF ) treated with ...

In recent years, a pressing need to develop new, effective and safe drugs against tuberculosis ( TB ) has continued. ...

Adjuvant chemotherapy with Vinorelbine plus Cisplatin ( VC ) improves survival in resected non-small-cell lung cancer ( NSCLC ), but ...

Evolocumab ( Repatha ) is a fully human monoclonal antibody that inhibits proprotein convertase subtilisin/kexin type 9 ( PCSK9 ). ...

Early diagnosis and treatment of acute promyelocytic leukemia ( APL ), the M3 subtype of acute myeloid leukemia ( AML ...

One of the most exciting features of immune checkpoint inhibitors ( ICIs ) is that they provide impressive tumour responses ...

Statin intolerance has been a major limitation in the use of statins, especially at higher doses. New effective treatments are ...

Dalbavancin ( Xydalba ) is a antibacterial treatment for patients with complicated skin and soft tissue infections ( cSSTI ) ...

Sevelamer carbonate ( Renvela ), a buffered form of Sevelamer hydrochloride ( Renagel ), is an orally administered non-absorbed phosphate-binding ...

Peginterferon beta-1a ( Plegridy ) is a new therapy that belongs to the same Interferon class as several medications that ...

Additional results from AMAGINE-1, a pivotal, multi-arm phase 3 trial evaluating two doses of Brodalumab in patients with moderate-to-severe plaque ...

European Commission has granted marketing authorisation for Relvar Ellipta, which is now licensed across 31 European countries for the following ...

According to researchers from the University of Toronto and Manchester University an estimated 4,837,000 asthmatics with allergic bronchopulmonary aspergillosis ( ...

Merck has announced the presentation of early interim results from a single-arm, open-label phase IB study that has so far ...

Developing resistance to chemotherapy is a nearly universal, ultimately lethal consequence for cancer patients with solid tumors, such as those ...

Idenix Pharmaceuticals has announced that it has received verbal notice from the FDA ( Food and Drug Administration ) that ...

Achillion Pharmaceuticals has announced sustained viral response ( SVR4 ) results of 85 to 100% from an ongoing multi-dose Phase ...